Opus Point Partners Management’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Opus Point Partners Management’s Portfolio PLXP Stock Details PLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,125	Closed	-$280K	–	63
2015 Q4	$280K	Buy	+3,125	New	+$300K	0.19%	54

Other funds holding PLXP

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Lone Star Value Management Old Greenwich, Connecticut $52.7M AUM 30.18% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Russell Frank Company Seattle, Washington $56.9B AUM 2.13% 1-Year Est. Return

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Timpani Capital Management Milwaukee, Wisconsin $209M AUM 62.15% 1-Year Est. Return

Opus Point Partners Management's PLXP Position: Q1 2016 in Review

Opus Point Partners Management sold out of PLx Pharma Inc. Common Stock (PLXP) in Q1 2016, closing a stake of 3,125 shares — an estimated $280K sold.

Opus Point Partners Management first reported a position in PLXP in Q4 2015 and held it in 1 quarter. The position peaked at $280K in Q4 2015. 33 funds tracked by Wall St. Rank hold PLXP as of Q1 2016.

Opus Point Partners Management reported no remaining PLx Pharma Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
Opus Point Partners Management sold 3,125 PLx Pharma Inc. Common Stock shares in Q1 2016, an estimated $280K.
Opus Point Partners Management first reported a position in PLx Pharma Inc. Common Stock in Q4 2015 and held it in 1 quarter.
Opus Point Partners Management's PLx Pharma Inc. Common Stock position peaked at $280K in Q4 2015.
33 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q1 2016.

Based on Opus Point Partners Management's 13F filing for Q1 2016, filed 13 May 2016.